The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
Benzinga · 06/05/2022 20:09
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 36 companies achieved new lows for the year.
Benzinga · 05/31/2022 16:06
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/31/2022 12:19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/31/2022 11:23
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.
Benzinga · 05/30/2022 18:03
20 Stocks Moving in Thursday's Pre-Market Session
Gainers TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares rose 51.2% to $0.9603 in pre-market trading after dipping 18% on Wednesday.
Benzinga · 05/26/2022 10:46
GRPN, GNCA and LAB among mid-day movers
=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN)
Seekingalpha · 05/25/2022 16:49
HAPP Stock Soars 38% as Happiness Development Embraces EVs
Investor Place · 05/25/2022 15:03
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
Investor Place · 05/25/2022 14:38
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 05/25/2022 12:08
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Investor Place · 05/25/2022 11:39
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading.
Benzinga · 05/25/2022 10:10
Three weeks after layoffs, Genocea shuts down entirely
The Cambridge company made the decision just three weeks after announcing it was laying off 65% of its staff and exploring a sale.
American City Business Journals · 05/24/2022 16:25
50 Stocks Moving In Tuesday's Mid-Day Session
 Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million.
Benzinga · 05/24/2022 16:10
Genocea Closes Shop, Delists From NASDAQ
Benzinga · 05/24/2022 13:31
Genocea stock crashes 64% on winding down of operations, Nasdaq delisting
Genocea Biosciences (NASDAQ:GNCA) said its board voted to wind down the company's ongoing operations and terminate the remaining employees except those necessary to complete an orderly wind down. In April,
Seekingalpha · 05/24/2022 12:41
Genocea Announces Wind Down Of Operations And Delisting From NASDAQ
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations
Benzinga · 05/24/2022 12:15
BRIEF-Genocea Announces Wind Down Of Operations And Delisting From Nasdaq · 05/24/2022 12:12
Genocea Biosciences To Wind Down Operations; Shares Fall
MT Newswires · 05/24/2022 09:53
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday.
Benzinga · 05/23/2022 10:13
Webull provides a variety of real-time GNCAQ stock news. You can receive the latest news about Genocea Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.